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Effectiveness of Antimalarial Drugs
J. Kevin Baird, Ph.D.

t

he opening of the panama canal in 1914 initiated an era in
which efforts to control malaria were aimed at the anopheline mosquito. The
World Health Organization’s Global Malaria Eradication Campaign in the
1950s and 1960s marked the apex of these efforts. The use of dichlorodiphenyltrichloroethane (DDT) rid vast areas of endemic malaria virtually everywhere except in subSaharan Africa. The eradication strategy was abandoned in 1969, because it came to be
considered logistically, socially, and politically impractical, especially given public concern about the effects of DDT on the environment. It took two decades and a global resurgence of malaria before a new strategy emerged, one that was focused on treatment
rather than prevention.1 This treatment strategy is currently being debated, and its efficacy is unproved.2,3
Both the broad collapse of preventive efforts and the waning efficacy of standard antimalarial drugs4,5 account for the global resurgence of malaria. New therapies are available, but the use of older drugs persists for social, economic, and clinical reasons, despite
resistance of the organisms to the older drugs. Efforts to use new antimalarial drugs may
be hampered by regulatory requirements or economic obstacles as well as by important
questions about safety for the large numbers of patients who treat themselves. Public
health agencies continue to support the distribution of older therapies, despite strong
criticism from scientists conducting research on the disease and its treatment and prevention.6
In addition to inadequate drug efficacy, new therapies may fail because of inappropriate use, inadequate absorption, poor adherence, contraindications, intolerability, the use of counterfeit drugs or improper manufacture of drugs, or prohibitive cost.
Chloroquine and sulfadoxine–pyrimethamine, which for several decades were the
foundation of malaria therapy, had a low risk with respect to this array of problems.
However, the emergence and consolidation of resistance to these drugs eroded their
clinical usefulness.
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plasmodia
The coccidian genus plasmodium contains 172 species that infect birds, reptiles, and
mammals. Four species infect humans — Plasmodium falciparum, P. malariae, P. ovale,
and P. vivax. P. falciparum and P. vivax account for the vast majority of the 300 million to
500 million infections that occur each year. Endemic transmission takes place in most
tropical latitudes and reaches into temperate zones seasonally (Fig. 1). Although each
type of infection causes debilitating febrile illness, only P. falciparum carries a substantial risk of death; 1 million to 3 million deaths occur each year in regions of holoendemic infection in sub-Saharan Africa, most of them among infants and young children.
For plasmodia, humans are not the “definitive host,” a concept defined by parasitologists as the site where sexual recombination occurs. Instead, many species in the genus anopheles have that distinction. From the perspective of the parasite, humans are
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Figure 1. Risk of Plasmodium falciparum Malaria Worldwide.
Adapted from the Public Health Mapping Group, Communicable Diseases, World Health Organization,
November 2002.

simply a means of getting into mosquitoes, where
sexual recombination can occur. A full description
of the extraordinary complexity of this cycle is beyond the scope of this review. Figure 2 illustrates the
essential features of the cycle and the terminology
of antimalarial therapies.

in the developed world (Table 1). The developing
world requires distribution strategies for effective
therapies that overcome the availability of cheap
but ineffective drugs. The U.S. National Academies
made a core recommendation8 that governments
and international financial institutions should commit $300 million to $500 million per year within
five years to subsidize artemisinin-combined therextrinsic determinants
apies (an emerging family of antimalarial drugs,
of drug effectiveness
including artemether, artesunate and dihydroaravailability
temisinin) to achieve prices for the end user in the
Most developing nations license and make avail- range of 10 to 20 cents. Unless this recommendaable only the antimalarial drugs that are provided tion is followed, market forces will continue to drive
through national health programs.7 This approach the use of ineffective therapies.
often excludes relatively expensive or risky therapies, even for patients who may be able to afford a adherence
given drug and have access to medical supervision. Most people taking antimalarial drugs live in rural
The main factor affecting availability is economic regions of the developing world and are not super— the ability or inability to purchase a drug for vised by health professionals. A study conducted
broad distribution and the potential reluctance to among 1640 febrile patients with malaria in Burkina
use an agent because of an inability either to screen Faso9 showed that 69 percent were self-treated, and
in a study in Ethiopia, among 630 febrile patients
users or to monitor its quality.
Chloroquine and sulfadoxine–pyrimethamine with malaria, 67 percent were self-treated.10 Comcost less than 15 percent of the cost of the least ex- plex, inconvenient, or poorly tolerated antimalarial
pensive alternative agents and approximately 1 to regimens carry a substantial risk of inadequate ad2 percent of the cost of many of the agents marketed herence.11 Among 414 Brazilian patients, the risk of
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recurrent malaria correlated with self-reported poor
adherence,12 whereas among 632 Nigerian children
strict adherence correlated with clinical recovery.13
Convenient and easily understood packaging and
education of the patients alleviate poor adherence.
Owing to lengthy and complex regimens, currently
used therapies such as quinine and primaquine and
new combined therapeutic strategies14 challenge
the ease of adherence.

Blood
schizonticide

Gametocytocide

counterfeit and substandard drugs

Counterfeit antimalarial drugs pose a serious threat
in regions where the trade in pharmaceuticals is not
rigorously regulated. A survey conducted in Cameroon found insufficient or inactive ingredients in
38 percent of preparations labeled chloroquine, 78
percent of those labeled quinine, and 12 percent of
tablets labeled as an antifolate agent.15 A survey in
Southeast Asia involving 104 purchases of artesunate tablets found that 38 percent of the tablets contained no drug.16 The trade in counterfeit drugs undoubtedly results in many deaths, but it is lucrative
and carries little risk of imprisonment.17 The inadvertent marketing of substandard pharmaceuticals
poses another threat. In a survey of eight authorized
wholesalers in Tanzania selling combined sulfadoxine–pyrimethamine tablets, 11 percent of the tablets failed industry standards for content, and 44
percent failed dissolution testing.18

in trinsic determinants
of drug effectiveness
stage specificity

Plasmodia pass through distinct stages of form,
function, location, clinical consequence, and susceptibility to antimalarial drugs (Fig. 2 and Table 1).
Drug activity ranges from narrow (e.g., the activity
of quinine against asexual blood stages) to broad
(e.g., the activity of primaquine against sexual and
asexual forms in the blood and liver). Moreover, the
range of stage-specific susceptibility differs among
species of plasmodia — for example, chloroquine
kills the gametocytes of P. vivax but exerts no effect
against those of P. falciparum. These intrinsic properties define the recommended uses of antimalarial drugs.

Blood
Liver

Tissue
schizonticide

Figure 2. Antimalarial Drug Activity in the Life Cycle of Plasmodia.
Tissue-stage schizonticides kill the asexual stages developing in the liver, including liver schizonts (all species) and quiescent hypnozoites (Plasmodium
vivax and P. ovale), thus preventing primary or secondary attacks (relapses) of
clinical malaria. Blood-stage schizonticides interrupt asexual schizogony (mitotic division) in red cells, preventing or terminating clinical attacks of malaria. Gametocytocides kill or sterilize sexual stages in the blood, thus preventing infection of mosquitoes and transmission of the disease. Another class of
drugs, the sporontocides (which kill forms developing in the mosquito, including the sporozoites that infect humans), is not represented here, because
none are available for clinical use.

cle,20 at a rate that varies according to the susceptibility of the parasite to a given drug. For example,
artemisinin derivatives induce reductions of 104,
whereas tetracycline achieves a reduction by only a
factor of 10 with each cycle. The duration of exposure to a drug that is needed to eliminate infection
hinges on the intrinsic rate of decline and, more important, on the initial parasite burden.21 High levels
of parasitemia, as compared with a low burden, require longer exposure to effective drug levels and
have a relatively higher risk of treatment failure.22

parasite burden

Most patients with malaria carry a burden of 108 to pharmacokinetics
1013 parasites.19 Effective chemotherapy induces a A variety of factors affect the pharmacokinetics of
constant fractional decline with each asexual cy- antimalarial drugs. Variant alleles of the human
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Table 1. Cost, Convenience, and Primary Clinical Application of Antimalarial Therapies.
Cost ($)*

No. of
Doses

Duration
of Therapy

Chloroquine

0.11

3

48 hr

Blood-stage schizonticide

Sulfadoxine–pyrimethamine

0.14

1

Single dose

Blood-stage schizonticide

Quinine

0.97

21

7 days

Blood-stage schizonticide

Therapy

Mefloquine

Application

2.55

1

Single dose

Blood-stage schizonticide

48.00†

3

48 hr

Blood-stage schizonticide

Artemether–lumefantrine

9.12‡

6

48 hr

Blood-stage schizonticide, gametocytocide

Artesunate–mefloquine

5.00§

6

48 hr

Blood-stage schizonticide, gametocytocide

Artesunate–sulfadoxine–
pyrimethamine

2.40¶

3

48 hr

Blood-stage schizonticide, gametocytocide

Artesunate–amodiaquine

2.00¶

3

48 hr

Blood-stage schizonticide, gametocytocide

Primaquine

1.68

7–14

7 days–8 wk

Tissue-stage schizonticide, gametocytocide

Atovaquone–chloroguanide

* Unless otherwise indicated, the cost shown is the cost, in 2003 U.S. dollars, of medication for one adult treatment regimen, purchased in bulk, according to the International Drug Price Indicator Guide (IDPIG) (http://erc.msh.org/
mainpage.cfm?file=1.0.htm&module=dmp&language=English).
† U.S. commercial sources were surveyed; the cost is not available from the IDPIG.
‡ The cost shown is from the IDPIG; the combination is available through the World Health Organization (WHO) to qualified purchasers at a cost of $2.40 per adult treatment regimen.
§ The cost shown is from the WHO.
¶ The cost shown is from Arrow et al.8

gene for cytochrome P-450 2C19 (CYP2C19), for
example, correlate with slow or rapid metabolism
of some antimalarial agents. For example, chloroguanide, metabolized through the activity of
CYP2C19, was studied in 126 healthy, unrelated Nigerian subjects, of whom 5 percent had slow metabolism of the drug (8 percent of the normal rate).23
A study of Thai subjects taking oral contraceptives
reported that metabolism of chloroguanide was decreased by 34 percent,24 a finding that may be explained by inhibition of CYP2C19 activity by estrogen. Certain foods may also profoundly affect the
bioavailability (and toxicity) of certain antimalarial
drugs — for example, fatty foods affect the bioavailability of halofantrine and of the combination
of lumefantrine and artemether.
safety and tolerability

In rural health care centers, staff with relatively little
formal training may be responsible for taking care
of patients with malaria. The patients often have no
written medical history, and the centers have minimal capacity for laboratory screening for contraindications to particular medications. Worse still,
most of these people with malaria treat themselves
with antimalarial agents acquired over the counter
or passed from household to household.
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Any antimalarial drugs that are to be distributed in such regions need to be safe and well tolerated, and the risks associated both with the indicated use and with contraindicated or inappropriate
uses should be considered. Clinical studies supporting the licensing of new antimalarial drugs rarely
include highly vulnerable groups such as infants,
young children, and pregnant women.25 Thus, safety issues often drive the decision to continue distributing chloroquine or sulfadoxine–pyrimethamine,
despite substantial parasite resistance. Key data
with regard to the safety and tolerability of the most
commonly used antimalarial drugs are summarized
in Table 2.
immunity

The intersection of immunity to plasmodia and antimalarial drug activity is poorly understood. In a
study of Brazilian patients, self-reported poor adherence correlated with a risk of recurrence among
nonimmune persons (i.e., those with a first infection) but not among semi-immune persons (i.e.,
those with >4.8 years’ exposure to plasmodia).12
Among 80 Lao patients, the level of humoral immunity to P. falciparum and the risk of therapeutic
failure were correlated with the parasite count on
admission to the hospital and the length of time to
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Table 2. Safety and Tolerability of Available Antimalarial Drugs.*
Drug
Chloroquine
Sulfadoxine–pyrimethamine

Adverse Effects

Contraindications

Gastrointestinal upset, itching,
dizziness
—

Epilepsy

Death from overdose

Pregnancy, renal disease

Stevens–Johnson syndrome

G6PD deficiency, pregnancy, optic
neuritis, tinnitus, thrombocytopenic
purpura, blackwater fever

Hemolytic anemia, coma,
respiratory arrest, renal
failure

Quinine

Tinnitus, vertigo, headache, fever,
syncope, delirium, nausea

Mefloquine

Vomiting, headache, insomnia,
Depression, schizophrenia, anxiety
vivid dreams, anxiety, dizziness
disorder, any psychosis, irregular
heartbeat

Atovaquone–chloroguanide Gastrointestinal upset, headache,
stomatitis

Severe Adverse Events

Psychosis

Weight of <11 kg in children, pregnancy,
breast-feeding, renal impairment

None known

Artemether–lumefantrine

Dizziness, palpitations

Pregnancy, severe malaria

Impaired hearing

Artesunate–mefloquine

Vomiting, anorexia, diarrhea

Depression, schizophrenia, anxiety
disorder, any psychosis, irregular
heartbeat

None known

Halofantrine

Gastrointestinal upset,
prolonged QTc

Conduction abnormalities, pregnancy,
breast-feeding, infancy, use of
mefloquine

Cardiac arrest

Primaquine

Gastrointestinal upset, elevated
levels of methemoglobin

Pregnancy, G6PD deficiency,
breast-feeding

Hemolytic anemia

* Data in the table are from Taylor and White,25 Centers for Disease Control and Prevention,26 Phillips-Howard and Wood,27 and Wernsdorfer.28
G6PD denotes glucose-6-phosphate dehydrogenase, and QTc QT interval corrected for heart rate.

the resolution of fever.29 Djimde et al.30 showed that
the clearance of P. falciparum organisms carrying a
mutant transporter gene, pfcrt K76T, that was linked
with resistance to chloroquine correlated with acquired immunity in subjects in sub-Saharan Africa.
In subjects with relatively little immunity who were
infected with mutant parasites, the chloroquine
therapy failed more frequently than in those infected with the same genotype of P. falciparum organisms who had clinical immunity. However, such correlations do not directly link immune effectors with
drug activity; acquired immunity independently reduces the parasite burden, which is a well-known
determinant of antimalarial effectiveness.
The acquired immunity that occurs throughout
regions of holoendemic infection in sub-Saharan
Africa may explain the relatively late increase in resistance in that region. Most people at risk in South
America and Asia lack immunity and consequently
carry substantially higher parasite burdens than do
most Africans. Moreover, their symptomatic infections are generally treated far more often than are
asymptomatic infections among Africans. In Asia
and South America, these factors substantially increase the probability of the selection of resistant
genotypes.14

n engl j med 352;15

resistance

The parasites causing malaria exhibit a range of susceptibility to antimalarial agents. Several distinct
phenomena explain this range, including speciesspecific innate resistance (e.g., asexual blood stages
of P. falciparum lack susceptibility to primaquine,
whereas those of P. vivax appear to be sensitive to
it31); strain-specific innate resistance (e.g., that of
asexual liver stages of P. vivax from the island of New
Guinea against primaquine32); and acquired resistance. Of these, acquired resistance is the most important, because failure may occur even in the presence of complete adherence to the recommended
therapies. Studies in Senegal suggest that resistance
to chloroquine contributed to an increase by a factor
of 2 to 11 in mortality from malaria.33 In western
Kenya, case fatality rates were markedly higher
among children receiving chloroquine than among
those receiving other therapies.34
Most of the data on the responses of P. falciparum to therapy reflect this emphasis on acquired resistance. Nonetheless, P. vivax profoundly affects
public health outside Africa,35 and data are also
available that cover its resistance to chloroquine.
P. malariae and P. ovale infect relatively few people,
and little is known about acquired resistance in these
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species. Resistance to chloroquine in P. malariae was
reported from Indonesia36 but is apparently debatable.37
Genetic mutations among strains of plasmodia
have been linked with phenotypes of clinical resistance. Some studies challenge specific links between
genotype and phenotype in certain settings, but putative markers have emerged (Table 3); the extensive literature on this topic has been reviewed.38-43
Validated genetic determinants of resistance would
vastly improve surveillance and, thus, the effectiveness of resources for the treatment and control of
malaria.

drug resistance
The risk of resistance varies according to species,
strain, and drug. Estimates of risk are often confounded by the determinants already described.
Methods of estimating risk also vary. The following
estimates of the risk of treatment failure were distilled from many studies and should not be construed as quantitative region-specific risks, because
patterns of resistance vary tremendously, even within nations. Protocols that evaluate efficacy generally
follow the guidelines of the World Health Organization, which recommend a follow-up period of
7, 14, or 28 days.44 The timing of recurrent parasitemia or disease reflects the degree of resistance
— earlier failure represents higher-grade resistance.
Late recurrence may be confounded by reinfection,
especially in regions of intense transmission. Investigators in sub-Saharan Africa thus favor an in vivo
test with a duration of 7 or 14 days, whereas those
in other regions tend to favor a 28-day test or even
63-day test. Comparison of genotypes of the strains
causing original and recurrent parasitemias can be
used to address confounding by reinfection, but relatively few reporting clinics or laboratories have the
capacity to conduct such testing. Tests conducted
in Africa tend to report both parasitologic failure
(i.e., recurrent parasitemia after treatment, independent of clinical presentation) and the clinical failure
of treatment, whereas investigators elsewhere focus
on parasitologic failure.44
chloroquine

After an analogue that had been developed in Germany was captured in 1943, during World War II,
chloroquine quickly came into universal use as therapy for and prophylaxis against malaria.45 Chloroquine was highly effective, easily administered, and
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inexpensive and had good safety and tolerability.
However, resistance in P. falciparum appeared in the
late 1950s in Thailand and Colombia and emerged
in the 1970s in New Guinea and eastern sub-Saharan Africa. Today, resistance to chloroquine in malaria caused by P. falciparum occurs everywhere except
in Central America (and Hispaniola) and in some regions of southwestern Asia.
In sub-Saharan Africa, the risk of parasitologic
treatment failure with the use of chloroquine was
almost uniformly greater than 40 percent, whereas
the risk of clinical treatment failure tended to be
higher in the eastern and central portions of the African continent (typically >30 percent and often >50
percent, respectively) than in the west (typically <20
percent).8 Elsewhere, the rates of parasitologic failure at day 28 were 57 percent (of 209 evaluations)
in southwestern Asia,46-50 46 percent (2280 evaluations) in southern Asia,51-57 85 percent (223 evaluations) in Southeast Asia,58-66 and 66 percent
(137 evaluations) in South America.67-71 Prescribing
chloroquine monotherapy against this parasite in
any setting, except one in which its effectiveness has
recently been demonstrated, should be considered
irresponsible.
Resistance to chloroquine by P. vivax has
emerged, apparently having originated in New
Guinea, where failure rates now approach 100 percent.63 In contrast, surveys in Thailand reveal uniformly sensitive vivax malaria (not shown in Fig.
1).72 Chloroquine-resistant P. vivax may be characterized as endemic to the Indonesian archipelago,
especially in the east (including New Guinea), sporadic in the rest of Asia, and rare in South America.73
sulfadoxine–pyrimethamine

Sulfadoxine–pyrimethamine, which has potent efficacy against chloroquine-resistant and pyrimethamine-resistant P. falciparum, became available in
1971 and became the standard second-line therapy
against chloroquine-resistant falciparum malaria.
This combination acts synergistically against folate
synthesis, inhibiting dihydropteroate synthase and
dihydrofolate reductase. Although rare, idiosyncratic allergic reactions have occurred among users
of sulfa drugs, sulfadoxine–pyrimethamine has otherwise offered superior safety and tolerability, along
with the advantage of single-dose therapy. However, resistance to sulfadoxine–pyrimethamine was
recognized at the Thai–Cambodian border in the
1960s, and failures occurred in refugee camps in
Thailand in the 1970s.38
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Table 3. Mutations in Plasmodium falciparum That Are Associated with Resistance to Antimalarial Drugs.
Gene

Product

Genetic Determinant*

Drug

pfcrt

Transporter

Thr76

Chloroquine

pfmdr 1

Transporter

Tyr86

Chloroquine, mefloquine, quinine,
dihydroartemisinin†

Copy number

Mefloquine, artesunate

dhps

Dihydropteroate synthetase

Gly437, Glu540, Gly581

Sulfadoxine

dhfr

Dihydrofolate reductase

Asn108, Arg59, Ile51, Leu164

Pyrimethamine

cytb

Cytochrome b

Ser268

Atovaquone

* The predominant determinants, according to available data, are listed.
† The mutation is associated with increased sensitivity to this drug.

The rates of parasitologic failure of treatment
with sulfadoxine–pyrimethamine in sub-Saharan
Africa were relatively high in southern regions of
holoendemic infection (>50 percent) and low elsewhere (<5 percent, except in Cameroon, where the
rate of failure was 10 percent). The rates of clinical
treatment failure in sub-Saharan Africa were similarly distributed (<5 percent in the west and 8 to 34
percent in the east and south).8 Studies in Southeast
Asia indicated that the rates of parasitologic failure
at day 7 and day 28 were 36 percent and 49 percent,
respectively.74-79 Good efficacy (80 percent) persisted elsewhere — in southwestern Asia and on the
Horn of Africa, where no parasitologic failures were
reported among 362 evaluations80,81; in southern
Asia, where the failure rate was 18 percent (of 339
evaluations) by day 2855-57; and in South America,
where the failure rate was 9 percent (of 50 evaluations) by day 7, 14 percent (of 42 evaluations) by
day 14, and 6 percent (of 119 evaluations) by day
28.82-84 The risk of resistance to sulfadoxine–pyrimethamine is relatively high in Southeast Asia and
eastern Africa.
mefloquine

Mefloquine emerged as a successor to chloroquine
in the 1980s. Resistance appeared in regions at the
border between Thailand and Cambodia within a
few years, perhaps owing to widespread use of quinine, to which it is structurally related.38 Resistance
in that border region remains high.85 However, in
nearby regions resistance to mefloquine remains
relatively low. Smithuis et al.62 reported that, of 75
patients, more than 90 percent in the region of the
western border of Myanmar (Burma) responded
to mefloquine (at a dose of 15 mg per kilogram of
body weight). In another study, of 79 patients hos-

n engl j med 352;15

pitalized in Bangkok and treated with mefloquine
(25 mg per kilogram), 68 (86 percent) remained
free of parasitemia after 28 days.86 Similar efficacy
was observed in Bangladesh.56 However, a group
of Dutch marines in Cambodia who were receiving
mefloquine prophylaxis during the 1990s had high
attack rates of falciparum malaria.87 In contrast,
the protective efficacy of mefloquine among Indonesian soldiers in western New Guinea — where
the efficacy of chloroquine against P. falciparum and
P. vivax approaches zero63 — was 100 percent.88
The risk of the prophylactic or therapeutic failure
of mefloquine in Southeast Asia appears to be low
outside the shared borders of Thailand, Myanmar,
and Cambodia.
Few studies have evaluated the effectiveness of
mefloquine against falciparum malaria in Africa. In
the mid-1990s, Lobel et al.89 examined mefloquine
prophylaxis among 140 Peace Corps volunteers who
were infected by P. falciparum. Poor adherence explained most of the infections, but in five cases the
resistance appeared to be genuine (i.e., parasitemia
was present with >620 ng of mefloquine per milliter in plasma). Despite sporadic, well-documented
failures of mefloquine among travelers to Africa, the
drug remains effective there.
Studies conducted in coastal Peru and in the Amazon Basin among 153 subjects with P. falciparum
malaria who were receiving mefloquine (at a dose
of 15 mg per kilogram) revealed complete sensitivity.68,90,91 Despite occasional reports of resistance
in the Amazon basin, the available evidence shows
a low risk of resistance throughout South America.
Mefloquine has received adverse attention in the
media in recent years. The drug has been blamed for
suicides, homicides, and other personal tragedies
on the basis of anecdotal accounts, which, by their
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nature, cannot establish cause and effect. Well-controlled trials consistently indicate that mefloquine
given as prophylaxis is as well tolerated as other antimalarial drugs.92 Nonetheless, the drug has been
linked with a higher risk of insomnia, fatigue, and
adverse neuropsychiatric effects (e.g., depression
and anger) than other antimalarial drugs.93-95 The
risk appears highest among women, especially
those taking the drug for the first time and those
with a low body-mass index.96
quinine

of

medicine

cent rate of adherence.11 However, in Cambodian
villages, the rate of compliance with the same regimen was far lower — 11 to 20 percent — even after
an intervention to raise awareness about the need
for compliance.105
primaquine

Developed during World War II, primaquine remains the only licensed tissue-stage schizonticide
(Fig. 2) for the prevention of relapse after infection (standard therapy) or as presumptive therapy
against relapse after exposure to the risk of infection,
without evidence of infection (terminal prophylaxis). Recently recommended for use as prophylaxis,106 primaquine has a uniquely broad spectrum,
killing liver stages, asexual blood stages (of P. vivax31
but not P. falciparum107), and sexual blood stages.
In endemic regions, primaquine is widely used as a
gametocytocide to prevent infection of mosquitoes.
Despite more than 50 years of use in millions of
people per year, primaquine is still shrouded in confusion and genuine mystery. At least four different
regimens, some prescribed for only one week and
others for as long as eight weeks, are aimed at the
same objective of preventing relapse.108 Three factors largely explain the lack of uniformity: first, the
reluctance of health care programs to accept therapy that has a duration of two weeks; second, perceived issues of toxicity and tolerability; and third,
the use of a total dose, rather than a dosing schedule, as the primary determinant of efficacy. How the
same total dose of a rapidly eliminated drug kills
organisms irrespective of whether it is delivered over
a period of 7, 14, or 56 days defies explanation.
Resistance is not fully understood either. Resistance in asexual blood stages of P. vivax has long
been known109 but is of no clinical consequence.
Reports of resistance to tissue-stage schizonticidal
activity fail to consider or describe patients’ adherence, to exclude the possibility of reinfection, or to
address the possible recrudescence of chloroquineresistant strains. Lack of evidence of resistance to
primaquine in liver stages probably reflects a heavy
burden of proof rather than an absence of resistance.108

Jesuit priests in Peru in the 1500s learned from the
Incas that powder from the bark of the cinchona tree
relieved shivering with cold, and they supposed it
would also offer relief from the chills of malaria. Its
activity against the parasite, later shown to be due
to quinine, was unknown to them. Resistance to
quinine appears sporadically, and a moderate risk
of treatment failure appears to be limited to some
regions of Southeast Asia and New Guinea. Zalis et
al.97 suggested that there might be a link between
poor in vitro responses to quinine and diminished
clinical responsiveness in the Amazon basin, but
without supporting clinical data. Recent well-controlled trials of quinine monotherapy showed variable rates of efficacy against P. falciparum: 92 percent
in a group of 49 patients in Bangladesh,56 67 percent among 54 patients in western Thailand,98
and 80 percent among 30 patients in a clinic in
Bangkok.99 A seven-day regimen was more than 95
percent efficacious in Venezuela100 and Equatorial
Guinea.101 Rare reports of failure of intravenous
quinine for the treatment of severe or complicated
malaria have appeared sporadically.102
Oral quinine is used to treat uncomplicated malaria, generally over a period of three to seven days
in combination with another blood-stage schizonticide, typically tetracycline or doxycycline. Although
one study of 86 patients in Thailand showed the
superiority of a seven-day regimen combined with
tetracycline (a 100 percent efficacy rate) as compared with a five-day regimen combined with tetracycline (87 percent),103 studies performed elsewhere have shown complete efficacy with shorter
regimens combining quinine, doxycycline, and
primaquine.88,104
combined therapies
Poor adherence carries a high risk of treatment
against resistance
failure, particularly because quinine causes a syndrome of adverse effects known as cinchonism, Combined therapies, which constitute a widely
including primarily tinnitus, nausea, and vertigo. practiced strategy in the treatment of diseases such
A randomized trial in Thailand recorded a 71 per- as leprosy, tuberculosis, and infection with the hu-
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man immunodeficiency virus and which have long
been known to be effective against malaria,110 have
rarely been used in its treatment until recently.111
The use of more than one agent successfully requires
separate mechanisms of action against the same
stage of the parasite. Thus, because both sulfadoxine and pyrimethamine are folate antagonists, they
would not be considered a combined therapy. Similarly, combining a blood-stage schizonticide with
primaquine is not considered combined therapy,
because the drugs attack different stages of the parasite. The fixed combination of atovaquone–chloroguanide, which affects mitochondrial electron
transport and folate metabolism in asexual blood
stages, represents true combination therapy.112
Combined antimalarial therapies include old
and new drugs — old drugs in new combinations
(chloroquine and sulfadoxine–pyrimethamine), an
old drug combined with a new drug (amodiaquine
and artesunate), and new drugs in combination
(lumefantrine and artemether).113,114 Combination
therapy that includes artemisinin appears to be
potent and particularly useful in endemic regions;
extracted from the weed Artemesia annua, the artemisinins (primarily artemether, artesunate, and dihydroartemisinin) were developed in China during
the 1960s.
The artemisinins act very rapidly, reducing parasitemia by a factor of 104 with each cycle. Thus, for
a parasite burden in the range of 1012, only three
cycles are required to abolish parasitemia. The artemisinins are rapidly eliminated, and daily administration for a period of seven days (three cycles) is
required. Episodes of recrudescence follow briefer
regimens, but a seven-day regimen is considered to
be impractical. Therefore, treatment for a period of
three days with artemisinin combined with a slowly
eliminated companion blood-stage schizonticide
has been adopted. This three-day regimen of artemisinin reduces the parasite burden by a factor of
108 (leaving only 0.000001 percent of parasites
surviving to be abolished by mefloquine) (Fig. 3).
The artemisinins also exert activity against gametocytes, reducing the probability of transmission.
The use of combination therapies with artemisinin does not preclude the onset of drug resistance,
particularly since patients may not take the medication as directed. Thus, the multiple doses needed
with such combined therapies (typically six doses
over a period of three days) represent an important
potential pitfall. The emergence of resistant strains
may already be in progress. In vitro studies indicate
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Figure 3. Combination Therapies with Artemisinin
Derivatives.
The figure illustrates the rationale behind the use of an
artemisinin derivative combined with a slowly excreted
drug such as mefloquine for therapy against falciparum
malaria over a period of five weeks. Panel A shows plasma levels of mefloquine (blue line) and relatively high
levels of parasitemia caused by strains resistant to
mefloquine (solid red line) and sensitive to mefloquine
(dashed red line). Prescribed therapy eliminates the sensitive but not the resistant infection. Panel B shows the
importance of parasite burden as a determinant of drug
effectiveness, indicating the elimination of both sensitive
and resistant infections at lower levels of burden. Panel C
shows the quick inhibitory effect of a short regimen of an
artemisinin derivative (black line), but, owing to its short
plasma half-life, the drug cannot completely eradicate the
parasite. Panel D shows the effect of combining an artemisinin derivative (black line) with a drug such as mefloquine (blue line): a quick “knockdown” of the parasite
burden by the artemisinin derivative allows the sloweracting and more slowly excreted mefloquine to exert activity against a greatly diminished parasite burden.
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diminished susceptibility to artesunate among
Asian isolates.41 Isolates from western Cambodia,
where combination therapies with artemisinin derivatives are widely used, show diminished susceptibility to the combination of mefloquine and artesunate, as compared with isolates from eastern
Cambodia.115 In contrast, in the 1990s in some regions bordering western Thailand, combination
therapies with artemisinin derivatives were deployed as first-line therapy with excellent efficacy
(more than 90 percent), and this success appears to
be stable.116 Where more resources are available,
including medications, resistant strains have been
slower to develop. Where both medication and an
effective health care infrastructure are present, resistance can be controlled. Such economic and
personnel issues may explain the contrasting findings with regard to rates of resistance to combination therapies with artemisinin derivatives.117 Thus,
supplying these therapies in the setting of an adequate health care infrastructure would seem the best
way to prevent the onset of resistance.
Patients with severe or complicated malaria often cannot take oral medication, and parenteral
quinine has been the standard approach to therapy.
Rectal artesunate may radically improve the care of
such patients, especially across the geographic expanses of regions of endemic infection where parenteral medications are neither available nor practical. Clinical trials indicated that rectal artesunate
(combined with another blood-stage schizonticide)
cleared parasitemia more quickly than parenteral
quinine and with equal efficacy.118,119
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summary
A global public health threat due to the resurgence
of malaria stems from a general collapse of vectorcontrol operations and from resistance to chloroquine or sulfadoxine–pyrimethamine. Recent surveys show rates of treatment failure higher than 50
percent for chloroquine in most affected regions,
as well as poor efficacy of sulfadoxine–pyrimethamine in sub-Saharan Africa and Southeast Asia.
Quinine and mefloquine remain effective therapies
everywhere except in some regions bordering Thailand. Resistance to primaquine — the only drug for
preventing relapse — probably occurs but has not
yet been confirmed. New drugs should be effective
among the poor, self-treating rural populations in
regions of endemic disease and should be provided
through programs that address issues of availability and cost, convenience and adherence, safety and
tolerability, and quality assurance. The combination
therapies with artemisinin derivatives represent the
present best efforts toward providing such therapeutic agents. These drugs deliver an inhibitory
effect that substantially reduces the probability of
selection for resistant parasites, as compared with
traditional monotherapies. However, widespread
distribution without complementary capabilities in
the delivery of health care places the clinical usefulness of these critical drugs in doubt.
The views expressed here are those of the author and do not necessarily reflect or represent those of the U.S. Navy or the Department
of Defense.
I am indebted to Dr. Stephen L. Hoffman (Rockville, Md.) and Dr.
Chansuda Wongsrichanalai (Bangkok) for thoughtful reviews of
this manuscript, and to Zoila Pretell at the Naval Medical Research
Center Detachment, Lima, Peru, for research resources.
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